Infectious Diseases Summit
July 13 - 14, 2017 - Baltimore CA USGTCbio
infogtcbio@gtcbio.com
Phone:6262566405
Dear Colleague, We are pleased to invite you to attend GTCbio’s Infectious Diseases Summit, which will take place July 13-14, 2017 in Baltimore, MD. This event seeks to provide a forum for leaders to get the most comprehensive and wide-reaching perspective on issues, challenges, and advances in the field. The Summit begins with the Plenary Session: Rapidly Emerging Global Health Threats and disperses into the following three conferences: 6th Antiviral Drugs Research & Development I. Respiratory Virus Infections II. Treatment of Latent and Persistent Viral Infections III. Regulatory Challenges on Clinical Study Design and Considerations 15th Vaccines Research & Development I. Next-Generation Vaccine Technologies II. Vaccines for Infectious Diseases-Old & New Challenges III. Enhancing Immunity at Both Ends of the Age Spectrum IV. Panel: Clinical Trial Design During Epidemics 14th Anti-Infectives Partnering & Deal-Making I. Non-Traditional Approaches and Technologies in Anti-Infectives II. Innovative Strategies in Clinical Trials III. Panel: Funding & Partnering with US Government Agencies IV. Panel: Pricing and P&T Committee’s Role in Determining Novel Antibiotic Usage V. Panel: Pushing and Pulling: What Incentives Help Spark Innovation in Antibiotic Drug Discovery and Development? The end of the Summit comes together with the General Session: Public/Private Partnerships in Support of Global Health. In recent years, the field of infectious diseases has faced repeated challenges, and areas such as pricing and reimbursement, regulatory, and the discovery of novel antibiotics have yet to be overcome. However, recent deals and the reemergence of big pharma in the space has signaled that the landscape of infectious diseases is shifting: why is there a renewed interest in this field? What will it mean for biotech companies, government agencies, and other players? This Summit seeks to highlight all stages of the field, from research and novel therapeutics, to commercialization aspects and market activity. Colleagues from academia, industry, and government will gather at the interface of infectious diseases drug development to address current issues and find solutions to move the field forward into the future. We hope to see you in Maryland! Best regards, The 2017 Advisory Committee